We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    H-040-010
Previous Study | Return to List | Next Study

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00314132
Recruitment Status : Completed
First Posted : April 13, 2006
Results First Posted : December 5, 2012
Last Update Posted : December 6, 2012
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.

Condition or disease Intervention/treatment Phase
Encephalitis Japanese Encephalitis Biological: ChimeriVax-JE, Japanese Encephalitis vaccine Biological: 0.9% Saline Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2004 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Randomised, Double Blind, Multicentre, Placebo Controlled Phase III Study of the Safety and Tolerability Following Administration of Live Attenuated JE Vaccine (ChimeriVax™-JE)
Study Start Date : October 2005
Actual Primary Completion Date : November 2006
Actual Study Completion Date : November 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
All subjects received a single injection of placebo on Day 0.
Biological: 0.9% Saline
0.5 mL, Subcutaneous

Experimental: ChimeriVax™ JE 4 log10 PFU Vaccine
All participants received a single injection of ChimeriVax™ JE 4 log10 Plaque-forming unit (PFU) Vaccine on Day 0.
Biological: ChimeriVax-JE, Japanese Encephalitis vaccine
0.5 mL, Subcutaneous
Other Name: ChimeriVax™

Primary Outcome Measures :
  1. Number of Participants Reporting Treatment Related Adverse Events Post Vaccination With Either ChimeriVax™-JE or a Placebo [ Time Frame: Day 0 up to 30 days post-vaccination ]
    Adverse events were collected by means of diary cards and scripted interviews. All adverse events reporting was considered "actively solicited" through Day 30.

  2. Number of Participants Reporting Treatment Emergent Local Adverse Reactions and Treatment Emergent Systemic Reactions Post-vaccination With Either ChimeriVax™-JE or a Placebo [ Time Frame: Day 0 up to 30 days post-vaccination ]

    Treatment emergent local adverse reactions: Injection Site Pain, Itching, Erythema, Swelling, Induration, Skin Rash, and others as reported.

    Treatment emergent systemic reactions: Malaise, Headache, Myalgia, Feeling Hot, Chills, Fatigue, Dyspnea, Wheezing, Nausea, Vomiting, Diarrhea, Abdominal Pain and others as reported.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Informed consent obtained from the subject.
  • Aged 18 years or above at screening.
  • In good general health
  • Subject available for the study duration
  • For female subjects (of child bearing potential) a negative pregnancy tests at Screening and Day 0.

Exclusion Criteria:

  • A history of vaccination against or infection with JE.
  • Known or suspected immunodeficiency, use of immunosuppressive or antineoplastic drugs.
  • History of thymoma, thymic surgery (removal) or myasthenia gravis.
  • Clinically significant abnormalities on laboratory assessment
  • Anaphylaxis or other serious adverse reactions characterised by urticaria or angioedema to foods, Hymenoptera (bee family) stings, or drugs including vaccines).
  • Transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within six months of the Screening Visit or up to Day 30.
  • Administration of another vaccine or antiviral within 30 days preceding the Screening visit or up to Day 30.
  • Physical examination indicating any clinically significant medical condition.
  • Oral temperature >38°C (100.4°F) or acute illness within 3 days prior to inoculation.
  • Intention to travel out of the area for an extended period that may affect the subjects ability to attend clinic visits prior to the study visit up to Day 30.
  • Seropositive to hepatitis C virus (HCV) or HIV or positive for Hepatitis B Surface Antigen.
  • Lactation or intended pregnancy in female subjects.
  • Excessive alcohol consumption, drug abuse, significant psychiatric illness.
  • A known or suspected physiological or structural condition that compromises the integrity of the blood-brain barrier (e.g. cerebrovascular disease, multiple sclerosis, trauma, infection, inflammation of the brain or meninges).
  • Participation in another clinical study within 30 days of the screening visit for this study.
  • Employee of the study site, Sponsor or Clinical Research Organization (CRO) involved with the management of the study.
  • Any other reasons, which in the investigator's opinion, makes the subject unsuitable to participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00314132

Layout table for location information
United States, California
Burbank, California, United States, 92505
Costa Mesa, California, United States, 92708
Davis, California, United States, 95616
San Francisco, California, United States, 94102
Vallejo, California, United States, 94589
United States, Florida
Miami, Florida, United States, 33173
Orlando, Florida, United States, 32809
Pembroke Pines, Florida, United States, 33024
United States, Iowa
Iowa City, Iowa, United States, 52242
United States, Kansas
Overland Park, Kansas, United States, 66212
United States, Kentucky
Bardstown, Kentucky, United States, 40004
United States, Michigan
Livonia, Michigan, United States, 48152
United States, Missouri
Sprnigfield, Missouri, United States, 65802
United States, Nebraska
Omaha, Nebraska, United States, 68134
United States, North Carolina
Winston Salem, North Carolina, United States, 27109
United States, Texas
Fort Worth, Texas, United States, 76135
Darlinghurst, Australia, NSW 2010
Enoggera, Australia, QLD 4051
Heidelbeg West, Australia, VIC 3081
Kippa-Ring, Australia, QLD 4021
Mill Park, Australia, VIC 3082
Toorak Gardens, Australia, SA 5056
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Steven G Hull, MD Vince and Associates Clinical Research
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT00314132    
Other Study ID Numbers: H-040-010
First Posted: April 13, 2006    Key Record Dates
Results First Posted: December 5, 2012
Last Update Posted: December 6, 2012
Last Verified: December 2012
Keywords provided by Sanofi:
Japanese Encephalitis
Encephalitis virus
ChimeriVax™-JE Vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Encephalitis, Japanese
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Encephalitis, Arbovirus
Encephalitis, Viral
Central Nervous System Viral Diseases
Central Nervous System Infections
Infectious Encephalitis
Arbovirus Infections
Vector Borne Diseases
Virus Diseases
RNA Virus Infections
Flavivirus Infections
Flaviviridae Infections